🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

#EditorChoiceArticle Safety and Efficacy of Devices Delivering Inhaled #Antibiotics among Adults with Non-Cystic Fibrosis #Bronchiectasis: A Systematic Review and a Network Meta-Analysis by Dr. Sofia Tejada et al. from Vall d'Hebron Institut de Recerca 👉mdpi.com/2079-6382/11/2…

#Oncología | Un estudio incrementa la eficacia de la inmunoterapia en cáncer de mama redaccionmedica.com/secciones/onco…

✨ONLINE NOW Nature Cancer “LCOR mediates interferon-independent tumor immunogenicity and responsiveness to immune-checkpoint blockade in triple-negative breast cancer” by Toni Celia-Terrassa and Co. #breastcancer #Immunotherapy Here👇 rdcu.be/cJcDy go.nature.com/3icyE8x

📻 'Una investigación española logra incrementar la eficacia de la inmunoterapia para tratar el cáncer de mama' bit.ly/3N2TpS4 via Cadena SER #immunoterapia #càncerdemama @IMIM_research Nature Cancer Toni Celia-Terrassa Iván Pérez

Un estudi de l'@IMIM_research Hospital del Mar que publica Nature Cancer ha aconseguit transformar tumors resistents al tractament i curacions en models animals Incrementen radicalment l’eficàcia de la #immunoteràpia en #càncerdemama ➡️imim.es/noticies/1063

Congratulations to our labmates! 🙌 Iván Pérez Toni Celia-Terrassa

A study in Nature Cancer identifies ligand-dependent corepressor-low cancer stem cells driving tumor immunity and proposes LCOR induction with mRNA therapy as an enhancer of immunotherapy response. go.nature.com/3wjW8AL

Logran que la inmunoterapia en # cáncerdemama triple negativo incremente su eficacia gracias a la estrategia de ARN mensajero. #investigacion del Instituto Hospital del Mar de Investigaciones Médicas y del Hospital del Mar efesalud.com/inmunoterapia-…

Siguiendo con #ConoceCancerCSIC, hoy os presentamos al grupo de Pilar Navarro (Pilar Navarro Lab), investigadora del IIBB - CSIC y responsable del área de atracción de talento en Conexión Conexión Cáncer CSIC.

Thank you EMBO EMBL for the organisation of such a great #EESMetastasis...4 days of top science, ideas, inspiration, feedback and beers with great colleagues Amaia Cipitria Maria M Caffarel Toni Celia-Terrassa Dr. Sarah Young Queralt Vallmajó Martín Iván Pérez paloma bragado + no-twitter ones😉

Incredibly excited to share our article “Metastatic recurrence in colorectal cancer arises from residual EMP1+ cells” published today nature. I hope that you like it! A big thank you to all the co-authors for all their hard work! Highlights in the🧵 1/20 nature.com/articles/s4158…

18th ASEICA international congress in Santiago de Compostela. Good science and networking thanks to ASEICA 🧬

La recerca en immunoteràpia en càncer que es desenvolupa a @IMIM_research ha rebut un nou impuls gràcies a la donació de 43.250 euros de la Fundació AMICS Hospital Mar 👉bit.ly/3FNY6wg Xavier Trias Joaquín Arribas Toni Celia-Terrassa Iván Pérez Maribel Pérez

🔬 Impuls a l' #investigación en #inmunoterapia en #cáncerdemama amicsdelhospitaldelmar.org/noticies/129/l… @IMIM_research Joaquín Arribas Xavier Trias Toni Celia-Terrassa Maribel Pérez Iván Pérez Cuéntame cómo pasó

Best collaborative CIBER ONC project. Predoctoral scientist. Congratulations, Iván and Toni!

Way to go Iván Pérez👏👏👏 @IMIM_research Very proud of our PhD student recognized by CIBERONC for his work on LCOR and immuno-evasive cancer stem cells in #Immunotherapy as the best CIBERONC PhD study of 2022. Amazing job and performance Iván, very well deserved! Study 👇

Ya es oficial!🥳 Estamos muy contentas de anunciar que somos las ganadoras del premio #VanguardiadelaCiencia La Vanguardia por nuestro estudio de detección precoz del #cáncerdepáncreas. Muchas gracias a todo el mundo que nos ha votado! @IMIM_research Conexión Cáncer CSIC IIBB - CSIC CSIC

Congratulations Iván Iván Pérez for your PhD Thesis🎉🧑‍🎓. Outstanding performance and professional/personal achievements. I can't be more proud of you! And thanks for the fantastic thesis committee: M. Serrano, A. Gros, and E. Batlle🙏 Now it's time for a big lab celebration🎉

Delighted to present initial translational results from the CANTÁBRICO study (phase IIIb trial of durvalumab plus platinum-etoposide as 1st line for patients with ES-SCLC) at #ELCC2023 #SCLC ⁦Hospital del Mar⁩ ⁦@IMIM_research⁩ ⁦⁦AstraZeneca España⁩

Very happy to have the first version of the manuscript from my PhD work in Bigas/Espinosa Lab out!We identify a novel function of the classical NF-κB inhibitor IκBα in regulating pluripotency heterogeneity in mESCs HMar Research Institute Josep Carreras Leukaemia Research Institute (IJC) bioRxiv Cell Biology #pluripotency #development